GI Insights

Over the last few years, we've only started to gain an understanding of how gender affects our approach to GI illnesses. And since a greater awareness of these differences will help us become better clinicians, Dr. Peter Buch speaks with Dr. Asma Khapra about how we can optimize our approach to managing common GI illnesses in our female patients.

What's on the horizon for the management of inflammatory bowel disease? To share some of the latest clinical trial updates, Dr. Neil Nandi is joined by Dr. Peter Higgins from the University of Michigan to explore some of the latest developments in early detection tools and treatment strategies for patients with IBD.

What's on the horizon for the management of inflammatory bowel disease? To share some of the latest clinical trial updates, Dr. Neil Nandi is joined by Dr. Peter Higgins from the University of Michigan to explore some of the latest developments in early detection tools and treatment strategies for patients with IBD.

Immune checkpoint inhibitors have evolved the treatment landscape for cancer, but we need to consider the GI side effects. To do so, Dr. Peter Buch is joined by Dr. Rashid N. Lui to assess the GI impacts of ICIs and how to manage them.

As clinicians, providing the best quality of care is paramount. But when it comes to procedure-intensive specialties, medical malpractice is a notable concern. So what do we need to know about the common malpractice claims in the GI field, and how can we mitigate the risk of those claims? To find out, Dr. Peter Buch is joined by Dr. Michael Weinstein, President and CEO of Capital Digestive Care.

Proton pump inhibitors (PPIs) are among the most frequently prescribed medications in the world, but in many instances, they may be unnecessary. So how might this impact our patients’ health, and how can we identify those patients who should be prescribed PPIs? Dr. Peter Buch is joined by Dr. Alexander Perelman to talk about the overuse of PPIs.

Primary biliary cholangitis, which was formerly known as primary biliary cirrhosis, is a chronic disease that progresses over time. Fortunately, much progress has been made in that many patients are being diagnosed and treated much earlier than before. But what exactly has changed when it comes to our detection and treatment of this disease? Dr. Peter Buch is joined by Dr. Hetal Karsan, Adjunct Professor of Medicine in the Division of Digestive Diseases at Emory University School of Medicine, to discuss key updates in primary biliary cholangitis care.

As clinicians, we know that adherence to treatment regimens is associated with improved outcomes in our patients with inflammatory bowel disease (IBD). However, many factors can contribute to a patient's nonadherence, and understanding what those factors are, especially in underserved patient populations, is an important category of care that we need to keep in mind. Tune in to hear Dr. Peter Buch speak with Dr. Lea Ann Chen about how we can manage IBD in underserved patient populations.

Since only 70 percent of initial eradication attempts of Helicobacter pylori are successful, it’s important for us to understand the factors that might be contributing to this startling statistic. That’s why Dr. Peter Buch speaks with Dr. Erick Argueta about why Helicobacter pylori can be difficult to eradicate and how we can best treat this infection.

Inflammatory bowel disease (IBD) among the elderly is common, and when compared to IBD in younger patients, it’s characterized by a different disease course and has an increased risk of mortality. So how can we achieve better outcomes for our elderly patients? Dr. Peter Buch is joined by Dr. Benjamin Cohen, Co-Section Head and Clinical Director for Inflammatory Bowel Disease at the Cleveland Clinic, to discuss evaluation and treatment strategies for our elderly patients with IBD.